1,191 material Form 8-K filings that 965 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
At its 2026 Annual Meeting on September 24, 2026, Korn Ferry stockholders elected all nine director nominees, approved an advisory resolution on executive pay, approved the amended and restated 2022 Stock Incentive Plan, and ratified Ernst & Young LLP as auditor for fiscal 2027. The amended plan adds 1,400,000 shares for stock-based awards and extends its term to September 24, 2036, which sets the terms under which future equity may be granted to employees and directors.
Plan adds 1,400,000 shares available for stock-based awards and extends term to September 24, 2036
Plan approved with 43,102,365 votes for and 2,155,490 against
Executive compensation advisory resolution approved with 43,800,129 votes for and 1,145,915 against
Ernst & Young LLP ratified as independent auditor for fiscal 2027 with 46,296,359 votes for
On September 28, 2026, AAR agreed to acquire a 65% controlling interest in MRO Holdings, an aircraft maintenance provider, for an estimated cash price of $1,819,174,310 plus Series A preferred stock with an agreed value of $780,825,690, subject to adjustments and closing conditions including regulatory approvals. The deal is expected to close in AAR's fiscal third quarter ending February 2027 and is to be funded partly by about $2.1 billion of new debt, which AAR expects to take net leverage to about 3.6x at closing. The filing also notes that a private investment in public equity offering may dilute existing stockholders, and the company's fiscal 2026 adjusted EBITDA was $401.1 million, up from $324.2 million.
Estimated cash purchase price of $1,819,174,310 and Series A preferred stock with an agreed value of $780,825,690, plus a $22,500,000 escrow deposit
Implied enterprise value of $4.0 billion; AAR expects about $2.1 billion of new debt financing and net leverage of about 3.6x at closing
Expected close in fiscal third quarter ending February 2027, subject to regulatory approvals; termination fee of $100,000,000 ($150,000,000 if the outside date is extended) applies if competition approvals fail
Press release shows fiscal 2026 net income of $187.7 million versus $12.5 million in fiscal 2025, and adjusted EBITDA of $401.1 million versus $324.2 million
NETSOL reported record full-year fiscal 2026 revenue of $74.4 million, up 12.5% and above its $73 million guidance, and operating income nearly doubled to $6.9 million. GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, roughly flat with the prior year's $0.25, as a foreign exchange swing and higher non-controlling interest offset operating gains. The company also issued fiscal 2027 guidance calling for revenue growth of 13% to 16%.
Fourth-quarter fiscal 2026 revenue rose 12.5% to a record $20.7 million, and operating income rose 40.2% to $4.5 million.
Full-year GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, compared with $2.9 million, or $0.25, a year earlier.
Fiscal 2027 guidance: revenue growth of 13% to 16%, gross margin of approximately 50% or better, and adjusted EBITDA growth of 15% to 25%.
Cash was $27.1 million at June 30, 2026, and operating cash flow was $13.9 million versus $0.4 million a year earlier.
Chesapeake Utilities designated Jeffrey S. Sylvester, its Senior Vice President and Chief Financial Officer, as principal financial officer, and Michael D. Galtman, its Senior Vice President and Chief Transformation Officer, as principal accounting officer, both on September 28, 2026. The filing states no compensation changes were made in connection with either designation, so the change is administrative in nature for shareholders.
Jeffrey S. Sylvester was designated principal financial officer on September 28, 2026; he was appointed CFO effective July 1, 2026
Michael D. Galtman was designated principal accounting officer on September 28, 2026; he became Chief Transformation Officer effective April 1, 2026
Galtman previously served as Chief Accounting Officer from 2019 to April 2026
No compensation changes were implemented for either officer in connection with the designations
National Healthcare Properties said that on September 25, 2026, the purchaser's termination rights under a July 15, 2026 agreement to sell its 40 outpatient medical facilities for approximately $531 million ended. The company expects the sale to close in the fourth quarter of 2026, subject to customary closing conditions. For shareholders, the filing confirms the pending sale is moving toward closing but does not describe its effect on earnings or future results.
Sale of 40 outpatient medical facilities for approximately $531 million, before transaction expenses, prorations and adjustments
Purchaser's termination rights terminated on September 25, 2026, under the purchase and sale agreement dated July 15, 2026
Closing expected in the fourth quarter of 2026, subject to customary closing conditions
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026, with some portions possibly omitted
Clearway Energy subsidiary Swan Purchaser LLC agreed on September 23, 2026 to buy membership interests in Swan TargetCo LLC from an affiliate of Clearway Energy Group for a base price of about $230 million in cash, subject to adjustments. Swan TargetCo will indirectly own Swan Solar, which is developing a 650-megawatt solar facility in Bates County, Missouri, and the deal is expected to close in the third quarter of 2028 subject to conditions.
Base purchase price of approximately $230 million in cash, subject to adjustments tied to a financial model with minimum economic thresholds
Swan Solar is developing and constructing a solar photovoltaic facility with about 650 megawatts of installed capacity in Bates County, Missouri
Closing expected during the third quarter of 2028, subject to customary conditions and third-party actions
Seller is Swan CE Seller LLC, an affiliate of Clearway Energy Group LLC; Purchaser will hold 100% of Target Company class A units at closing
Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.
Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
U.S. Physical Therapy entered a 45-month forward-starting interest rate swap with Bank of America on September 22, 2026, with an initial notional amount of $170.6 million. The swap fixes the variable interest rate on the term debt under its April 14, 2026 credit agreement, starting June 30, 2027, when its existing swap expires. The filing describes this as a hedge on borrowing costs, with no earnings figures disclosed.
Swap notional amount: $170.6 million, reflecting term loan amortization as of the effective date
Company pays a fixed rate of 4.578% per annum and receives one-month SOFR; swap effective June 30, 2027
Swap terminates April 14, 2031; Bank of America is counterparty and Administrative Agent under the credit agreement
The Trustee issued a release answering Unit Holder questions about administrative expenses, a 2017–2020 joint interest audit adjustment, Hilcorp capital spending, and liquidity. It states general and administrative expenses fell by about $976,000 year over year, mainly due to costs from the 2024 trustee transition that did not recur, and that the $2,000,000 Texas Bank credit facility, maturing May 21, 2027, is being discussed for extension, renewal, or replacement.
General and administrative expenses decreased by approximately $976,000 year over year, mainly from non-recurring 2024 trustee transition costs
Outstanding principal on the $2,000,000 Texas Bank Line of Credit was approximately $1,075,400 as of September 18, 2026; the facility matures May 21, 2027
The Trustee is in talks with Texas Bank and evaluating other financing sources, including other commercial lenders, Unit Holders, and private lenders
National newswire distribution of monthly press releases will be restored, beginning with the October 2026 release
AAR CORP. reported first-quarter fiscal 2027 results for the period ended August 31, 2026, with sales up 24% to $918.0 million and GAAP diluted EPS of $1.00, compared with $0.95 a year earlier. The company also announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings, and the guidance it gave excludes that acquisition's effect, so shareholders face both the quarterly gains and a large pending deal.
Q1 sales of $918.0 million, up 24% from $739.6 million; GAAP net income of $40.1 million versus $34.4 million
Adjusted diluted EPS of $1.49, up from $1.08; adjusted EBITDA of $116.5 million, up 34%
Full-year fiscal 2027 sales growth guidance (ex. LCP) changed to low teens from low double-digits to low teens; second-quarter sales growth guidance set at 14% to 16%
Net debt of $780.5 million and net leverage of 1.81x at August 31, 2026; acquisition expenses rose to $19.6 million from $4.4 million
StandardAero announced that Chief Operating Officer Kimberly Ernzen will no longer serve in that role as of September 28, 2026. She will stay employed through December 31, 2026 to support the leadership transition, and the company expects to enter into a transition agreement with her, terms not yet determined.
Kimberly Ernzen ceases to be Chief Operating Officer effective September 28, 2026
Ernzen remains employed and supports the leadership transition through December 31, 2026
Transition agreement terms have not yet been determined by the company
At an Analyst Day on September 28, 2026, CAMP4 Therapeutics described the design and timing of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder and gave a pipeline update. The company expects to dose the first patient by the end of 2026 and targets topline data in the first half of 2028, so the update sets out timelines but reports no clinical results or financial figures.
The company expects to dose the first patient in the ASCEND trial by the end of 2026 and targets topline data in the first half of 2028.
The trial plans three multiple ascending dose cohorts with a minimum of eight participants each, randomized 3:1 to intrathecal CMP-002 or a sham procedure.
The company expects to designate a development candidate in its SHANK3 program for Phelan-McDermid Syndrome in 2027, citing more than 45,000 US patients.
IDT reported fiscal fourth-quarter 2026 revenue of $339.0 million, up 7%, and income from operations of $33.2 million, up 52%. For the full fiscal year, revenue rose 5% to $1,298.0 million and GAAP diluted EPS increased to $3.46 from $3.01. The company guided fiscal 2027 Adjusted EBITDA to $176 million to $180 million, while full-year operating cash flow fell to $91.1 million from $127.1 million.
Q4 2026 revenue rose 7% to $339.0 million; income from operations rose 52% to $33.2 million
FY 2026 revenue rose 5% to $1,298.0 million; income from operations rose 21% to $121.2 million
FY 2026 GAAP diluted EPS was $3.46, up from $3.01 in FY 2025
FY 2027 outlook: Adjusted EBITDA of $176 million to $180 million; FY 2026 net cash from operations fell to $91.1 million from $127.1 million
Graphic Packaging Holding Company appointed Aditya Gandhi as Vice President and Chief Accounting Officer effective September 28, 2026, reporting to Interim Chief Financial Officer Charles D. Lischer. Gandhi previously served as Chief Accounting Officer at AptarGroup and Sonoco Products Company, and the filing discloses his pay package, which includes restricted stock units and a cash sign-on bonus.
Gandhi, age 46, joins as Vice President and Chief Accounting Officer, reporting to Interim CFO Charles D. Lischer
One-time restricted stock unit grant valued at approximately $715,000, vesting ratably over three years
Cash sign-on bonus of $105,000
Prior roles include Chief Accounting Officer at AptarGroup (from June 2026) and Sonoco Products Company (August 2022 to May 2026)
Precision Optics reported fiscal 2026 revenue of $31.5 million, up about 65%, and a narrower net loss of $3.6 million, or $0.43 per share, compared with $5.8 million, or $0.85 per share, a year earlier. The company guided fiscal 2027 revenue to $30 million to $33 million, similar to fiscal 2026, citing a pause in orders from an existing satellite customer that it expects to partly offset with other programs and a stronger second half. For shareholders, the results show strong growth and smaller losses, but the outlook projects no revenue growth for the coming year.
Fourth quarter ended June 30, 2026: revenue of $8.8 million, up about 42% from $6.2 million a year earlier, with a net loss of $0.1 million versus $1.4 million.
Fiscal 2026 revenue of $31.5 million, up about 65% from $19.1 million; net loss of $3.6 million, or $0.43 per share, versus $5.8 million, or $0.85 per share.
Fiscal 2027 revenue guidance of $30 million to $33 million, similar to fiscal 2026, reflecting a pause in orders from an existing satellite customer.
Fiscal 2027 Adjusted EBITDA guidance of $(1.2) million to $(1.7) million loss, compared with a $(2.1) million loss in fiscal 2026.
Teledyne said Vice Chairman Jason VanWees will retire effective February 1, 2027. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, will become Corporate Vice President of Investor Relations and Mergers and Acquisitions effective November 1, 2026. VanWees has led the identification and acquisition of 75 businesses for cumulative consideration of $12.8 billion, so the change affects the company's acquisition and investor communication roles.
Jason VanWees, Vice Chairman, retires effective February 1, 2027, at age 55
Mary Grace DeForest appointed Corporate Vice President of Investor Relations and M&A, effective November 1, 2026
DeForest is SVP and General Manager of Teledyne Microwave, with 880 employees and annual revenue of $320 million
VanWees led acquisitions of 75 businesses for cumulative consideration of $12.8 billion
PetMed Express increased the share reserve under its 2024 Inducement Incentive Plan by 500,000 shares, bringing the total to 850,000, effective September 27, 2026. The increase covers equity grants promised to Jeffrey Allen Willard, the new Chief Executive Officer, whose start date is September 28, 2026, so the change adds potential dilution for shareholders.
Share reserve under the Inducement Incentive Plan rises by 500,000 shares to 850,000 total.
The increase matches 250,000 restricted stock shares plus 250,000 performance share units promised to CEO Jeffrey Allen Willard.
Willard's start date is September 28, 2026; the plan was amended and restated as of September 27, 2026.
No other changes were made to the original plan, per the filing.
Ready Capital Corporation said its subsidiary ReadyCap Holdings II closed a private placement of $225.0 million of 10.00% senior secured notes due 2031 on September 28, 2026. On the same day, an indirect subsidiary redeemed the entire $350.0 million of its 4.50% senior secured notes due 2026 at 100% of principal plus accrued interest. The filing is a financing refinancing update and does not report revenue, earnings or guidance.
New Notes: $225.0 million aggregate principal, 10.00% coupon, due 2031, closed September 28, 2026
Existing Notes: entire $350.0 million 4.50% senior secured notes due 2026 redeemed September 28, 2026
Redemption price: 100% of principal amount plus accrued and unpaid interest
Offering was previously priced and disclosed in a Form 8-K filed September 18, 2026
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.
Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Jefferies reported results for the quarter ended August 31, 2026, with net earnings attributable to common shareholders of $261 million, up from $224 million a year earlier, and total net revenues of $2.22 billion, up from $2.05 billion. Investment Banking and Equities reached record quarterly revenue, while Fixed Income and Asset Management declined. The board also raised the share buyback authorization to $250 million and declared a $0.40 quarterly dividend.
Total net revenues of $2.22 billion versus $2.05 billion in the prior year quarter.
Diluted earnings per voting common share of $1.08 versus $1.01; return on adjusted tangible shareholders' equity of 13.5% versus 13.6%.
Asset management fees and investment return of $34 million versus $84 million in the prior year quarter.
Quarterly dividend of $0.40 payable November 25, 2026; buyback authorization increased to $250 million.
Pathfinder Bancorp, Inc. declared a quarterly cash dividend of $0.10 per voting and non-voting common share, related to the fiscal quarter ending September 30, 2026. Shareholders of record on October 16, 2026 will receive the payment on November 6, 2026.
Dividend amount: $0.10 per share on voting and non-voting common stock
Record date: October 16, 2026
Payment date: November 6, 2026
Dividend relates to the third quarter 2026 fiscal quarter
Hain Celestial's common stock was transferred from The Nasdaq Global Select Market to The Nasdaq Capital Market on September 24, 2026, and Nasdaq granted an additional 180-day period, to March 22, 2027, to regain the $1.00 minimum bid price. The company may need a reverse stock split, and it states there is no assurance it will regain or maintain compliance. Separately, Chief Accounting Officer Michael J. Ragusa plans to resign effective November 1, 2026, and CFO Lee A. Boyce will also take on the principal accounting officer role.
Stock transferred to The Nasdaq Capital Market at the opening of business on September 24, 2026, and continues to trade as HAIN
Nasdaq deficiency: closing bid price below $1.00 for 30 consecutive business days; second compliance period ends March 22, 2027
Compliance requires closing at or above $1.00 for at least ten consecutive business days; a reverse stock split may be used if necessary
Michael J. Ragusa resigns as SVP, Chief Accounting Officer, effective November 1, 2026; Lee A. Boyce takes on the principal accounting officer role
OPENLANE's subsidiaries amended two receivables purchase facilities on September 25, 2026, extending the termination date of each from January 31, 2028 to January 31, 2030. The filing describes the extension as a term extension and does not mention new borrowing capacity, pricing changes, or costs.
U.S. facility: Second Amendment to the Tenth Amended and Restated Receivables Purchase Agreement, signed September 25, 2026, extends termination date to January 31, 2030
Canadian facility: Amendment No. 4 to the Receivables Purchase Agreement dated March 1, 2023, signed September 25, 2026, extends termination date to January 31, 2030
Full amendment texts will be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026
Vail Resorts reported fiscal 2026 results for the year ended July 31, 2026, with net income attributable to the company falling to $147.5 million from $280.0 million, which it attributed mainly to weather. The company also gave fiscal 2027 guidance of $158 million to $233 million in net income and $805 million to $865 million in Resort Reported EBITDA, and said season pass unit sales were down about 12% through September 18, 2026.
Fiscal 2026 net income attributable to Vail Resorts was $147.5 million, versus $280.0 million a year earlier; Resort Reported EBITDA was $745.7 million, versus $844.1 million.
Fourth-quarter net loss attributable to Vail Resorts was $190.2 million, compared with a $182.4 million loss in the prior-year quarter.
Fiscal 2027 guidance: net income attributable to Vail Resorts of $158 million to $233 million and Resort Reported EBITDA of $805 million to $865 million.
Pass product units sold through September 18, 2026 fell about 12%, and sales dollars fell about 6%; the quarterly dividend is $2.22 per share, payable October 27, 2026.
MediciNova amended its office lease, extending the end date from January 31, 2027 to April 30, 2030, and agreed to rent increases starting February 1, 2027. The filing is an administrative lease change with no revenue, earnings, or guidance effect, though it commits the company to a longer occupancy period at higher rent.
Lease end date extended from January 31, 2027 to April 30, 2030, unless terminated earlier under the lease terms
Rent increases take effect February 1, 2027; the filing does not state amounts
Amendment dated September 23, 2026, with Newport Gateway Office LLC; original lease dated July 20, 2021 with Irvine Company LLC
Full amendment expected to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026
Adeia Inc. said Dipti Vachani, a former Arm Limited executive, will become chief executive officer and a board member effective October 12, 2026, succeeding Paul E. Davis, who is leaving to focus on his health and personal pursuits. The filing sets out her pay package, including a $730,000 base salary and an $11,000,000 target equity grant, along with severance terms and a consulting arrangement for Davis.
Vachani's CEO start date and board seat are both effective October 12, 2026; Davis's consulting agreement runs through December 31, 2026.
Vachani's offer letter provides a $730,000 base salary and a target bonus of 100% of base salary.
Target equity grants total $11,000,000, including a $4,400,000 time-based RSU award and a $6,600,000 performance-based RSU award.
Davis will receive a fixed consulting fee of $183,000.
On September 16, 2026, IQSTEL amended its 2025 agreement to acquire 51% of GlobeTopper, LLC, replacing a $500,000 payment originally due in restricted common stock with $500,000 in cash. The company must pay $80,000 within five business days, then $70,000 on the first business day of each of six following months, and the payments are secured by its GlobeTopper interest. If the company fails to cure a missed payment, the seller could seek to rescind the deal and take back the 51% interest, which would end the related earn-out obligations.
September 16, 2026: amendment replaces $500,000 in buyer shares with a $500,000 cash payment; the company has no further obligation to issue those shares
Payment schedule: $80,000 within five business days, then $70,000 on the first business day of each of six consecutive months
Missed payments not cured within 30 days after notice are an Event of Default; the seller may accelerate, foreclose on the collateral, or rescind and reclaim the 51% GlobeTopper interest
At its 2026 Annual Meeting on September 28, 2026, Phio Pharmaceuticals stockholders approved an amendment that raises the shares available under its 2020 Long Term Incentive Plan by 1,500,000 to a total of 2,452,017. Stockholders also re-elected six directors and ratified Grant Thornton, LLP as the independent auditor for 2026. The larger share pool allows more shares to be issued under the plan than before.
Plan Amendment approved; shares available under the 2020 Plan rise by 1,500,000 to 2,452,017.
Plan proposal vote: 1,155,945 for, 194,070 against, 34,468 abstained, and 3,823,097 broker non-votes.
All six director nominees elected, including Robert J. Bitterman, to serve until the 2027 Annual Meeting; Grant Thornton ratified with 5,087,608 votes for.
5,207,580 shares were present of 11,617,250 outstanding at the August 4, 2026 record date.
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
Par Pacific appointed Jerry Stumbo, formerly a Valero refinery general manager, as Executive Vice President of Refining and Logistics effective September 28, 2026. Richard Creamer, the current executive in the role, will serve as Senior Advisor until his planned retirement on or about April 1, 2027.
Jerry Stumbo, age 55, joins from Valero Energy, where he was VP and General Manager of the Port Arthur, Texas Refinery
Stumbo's Port Arthur refinery has approximately 435,000 barrels per day of throughput capacity
Richard Creamer retires effective on or about April 1, 2027, after serving as Senior Advisor from September 28, 2026
SCYNEXIS entered a contract with the U.S. Biomedical Advanced Research and Development Authority to develop its SCY-247 antifungal candidate, with potential non-dilutive funding of up to $214 million if all options are exercised. The initial base period provides approximately $18.5 million to advance SCY-247 into a Phase 2 study in patients with invasive candidiasis. The company says its SCY-770 development plans and cash runway into 2029 are unchanged.
Contract signed September 25, 2026; base period starts September 2026 with approximately $18.5 million
Potential total funding up to $214 million; BARDA may exercise up to six options extending the term up to ten years
Cost-share arrangement; company expects to fund its share of near-term SCY-247 costs within its existing operating plan
Full contract to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, with confidential terms redacted
Archrock's Vice President and Chief Accounting Officer, Donna A. Henderson, notified the company on September 23, 2026 that she intends to retire effective December 4, 2026. The filing does not name a successor or describe any financial impact, so the change's effect on shareholders is not yet clear.
Donna A. Henderson, Vice President and Chief Accounting Officer, plans to retire.
Notice was given to the company on September 23, 2026.
The Marygold Companies agreed on September 25, 2026 to be acquired by funds managed by Madison Dearborn Partners, with stockholders to receive $2.00 per share in cash, a premium of approximately 100% over the September 24, 2026 closing price. Stockholders holding about 75% of the voting power have already approved the merger by written consent, and the company's common stock will be delisted from NYSE American once the deal closes, which is expected in the first half of 2027 or earlier.
Stockholders will receive $2.00 per share in cash, a premium of approximately 100% over the September 24, 2026 closing price.
Written stockholder consent from holders of about 75% of voting power was delivered on September 25, 2026, satisfying the stockholder approval condition.
Common stock will stop trading on NYSE American after closing; the company will become privately held.
A termination fee of approximately $2.6 million may be payable by the company in certain circumstances; the Termination Date is June 7, 2027.
Effective September 28, 2026, World Gold Trust Services, LLC, sponsor of SPDR Gold Trust, appointed Joan A. Binstock to its Board of Directors and Audit Committee. The filing describes her background in accounting, finance and asset management, including past roles as a CPA, partner and chief financial officer at Lord, Abbett & Co. LLC.
Appointment effective September 28, 2026, to the Sponsor's Board of Directors and Audit Committee
Joan A. Binstock, age 72, is a licensed Certified Public Accountant and an Advisor at Lovell Minnick Partners, LLC since July 2018
Previously a Partner at Lord, Abbett & Co. LLC from 2000 to March 2018, where she served as Chief Financial Officer
Effective September 28, 2026, WGC USA Asset Management Company, LLC, sponsor of World Gold Trust and SPDR Gold MiniShares Trust, appointed Joan A. Binstock to its Board of Directors and Audit Committee. The filing describes a board-level appointment at the sponsor and does not describe any change to the fund's gold holdings or operations.
Appointment effective September 28, 2026 to the sponsor's Board of Directors and Audit Committee
Binstock, age 72, is a licensed Certified Public Accountant and former Chief Financial Officer of Lord, Abbett & Co. LLC
Binstock has held board roles at Morgan Stanley Direct Lending Fund since October 2019 and Brown Brothers Harriman US Mutual Funds since September 2019
Cincinnati Financial and subsidiary CFC Investment Company extended the expiration date of their credit agreement by one year, to October 10, 2031, under a September 25, 2026 amendment. All other terms of the 2025 credit facility are unchanged, so the filing reports no new borrowing or change in amounts.
Extension signed September 25, 2026 with Fifth Third Bank, N.A. as administrative agent
Expiration date moved to October 10, 2031, a one-year extension of the prior expiration
Credit agreement originally dated October 10, 2025; all other terms unchanged
Core Molding Technologies furnished slides from its September 28, 2026 investor day under Item 7.01, with the presentation attached as Exhibit 99.1 and posted on its website. The slides show trailing-twelve-month revenue fell from $377 million in 2022 to $254 million through the second quarter of 2026, while the company says its adjusted EBITDA margin improved from 8.7% in 2025 to 11.2%, which it presents as the result of its operating turnaround.
Trailing-twelve-month revenue of $254 million through Q2 2026, versus $274 million in 2025 and $377 million in 2022 per the slides
Adjusted EBITDA margin improved from 8.7% in 2025 to 11.2% per the slides; adjusted EBITDA is a non-GAAP measure
Slides cite $89 million of incremental annual revenue from new wins over 18 months and $210 million of annual revenue in active quotes
CEO Eric Palomaki and CFO Alex Panda are among presenters; the company says it aims to reach $500 million in revenue through economies of scale
Churchill Downs closed an amendment to its senior secured credit agreement that extends its revolving credit facility and Term Loan A from 2029 to 2031. It also closed a new $500 million senior secured Term Loan B due 2033, which the company plans to use to repay existing term loan and revolver borrowings, fund fees, and for general corporate purposes. The filing does not report earnings or guidance, so its effect on shareholders depends on the terms of the new debt.
Revolver and Term Loan A maturities extended from 2029 to September 25, 2031
New $500 million Term Loan B due September 25, 2033, at SOFR plus 175 basis points, issued at 99.875% of principal
Net proceeds to repay term loan B-1 and revolving loans, pay fees and expenses, and for working capital
Company plans to fund redemption of its 5.50% Senior Notes due 2027 on October 19, 2026 from the revolver
Greenpro Capital Corp. completed the sale of six subsidiaries, collectively the F&A Entities, to Ms. Chen Yanhong on September 28, 2026, for cash consideration of HK$3,500,000, or about US$446,486. The filing says the F&A Entities are reported as discontinued operations and that the company estimates a $130,679 loss on the sale, so shareholders will see a smaller continuing business with a one-time loss.
Sale completed September 28, 2026, for HK$3,500,000 (about US$446,486) in cash to Ms. Chen Yanhong.
The buyer is a director of four of the sold entities and holds 14 shares of Greenpro common stock.
The company estimates a $130,679 loss on the sale and a $5,303,075 reduction in additional paid-in capital from waived intercompany balances.
Pro forma six-month 2026 revenue from continuing operations was $431,828, versus $707,553 historically; the F&A Entities principally provided corporate advisory and company-secretarial services.
RideNow Group entered a $220 million senior secured term loan with Centerbridge-affiliated lenders and Alter Domus, using proceeds to fully repay its 2021 Oaktree-agented credit agreement. The new loans mature in September 2031 but carry steep interest, and the company is in advanced talks for a $50 million ABL revolver with Wells Fargo that is not yet committed.
$220 million senior secured term loans due September 25, 2031, funded September 25, 2026 to refinance the Existing Credit Agreement with Oaktree
Interest at Base Rate plus 7.375% or Adjusted Term SOFR (3.00% floor) plus 8.375%
Financial covenants include a first-lien net leverage ratio up to 4.80 to 1.00 and minimum liquidity of $15 million
Three unsecured promissory notes totaling about $10.0 million, held by SH Capital Partners, Mark Tkach and Face Canyon, were amended with 13.0% PIK interest maturing August 31, 2028
Getty Realty said its subsidiary bought a portfolio of 41 convenience store properties in Mississippi, North Carolina, South Carolina and Texas from Refuel affiliates for approximately $260.9 million, with the acquisition closing at the same time as the agreement was signed. The properties were leased back to Refuel under four 20-year triple net leases, and the company plans to fund the deal mainly with forward equity sales, a new unsecured term loan and property dispositions.
Purchase price of approximately $260.9 million for 41 convenience store properties, signed and closed on September 22, 2026
Refuel becomes the company's third largest tenant, representing approximately 7.7% of annualized base rent, pro forma for the transaction and other activity after June 30, 2026
Planned funding includes about $100.0 million from forward equity sales and about $100.0 million from a $200.0 million unsecured term loan expected to close in October 2026
Year-to-date investment reached approximately $455.2 million at a 7.1% initial cash yield, including this transaction
Core Molding Technologies said Michael J. Gayford has been promoted to Chief Operating Officer, effective immediately on September 28, 2026. He takes operational responsibility for the company's North American operations, and the Mexico operations executive will report to him. The filing describes this as an internal promotion, with no change in the company's reported financial results.
Michael J. Gayford named Chief Operating Officer effective September 28, 2026
Gayford joined the company in March 2023 as Vice President of Operations and was promoted to Executive Vice President of Operations in 2025
Arnold Alanis, Executive Vice President of Operations in Mexico, will report to Gayford
Gayford has more than 25 years of manufacturing, engineering and operational leadership experience, including more than 17 years in composite manufacturing
Quantum Corporation appointed James C. Clancy as Chief Operating Officer effective September 28, 2026, and he resigned from the board and its committees the same day. The filing sets out his pay package, including a $400,000 base salary, a 60% target bonus, 150,000 RSUs and an option on 400,000 shares, plus severance terms for both standard and change-of-control situations.
Clancy's offer letter sets a $400,000 annual base salary and a target bonus of 60% of base salary.
He received a grant of 150,000 RSUs and an option to purchase 400,000 shares, with grants expected around October 1, 2026.
Under the change-of-control agreement, a qualifying termination within 3 months before to 12 months after a change of control triggers 12 months of base salary plus 100% of target bonus.
Park Aerospace's Compensation Committee approved raising the annual base salary of Mark A. Esquivel, President and Chief Operating Officer, from $270,000 to $400,000. The increase takes effect September 28, 2026. The filing reports only this pay change, so its direct effect on shareholders is limited to the executive compensation it reflects.
Annual base salary rises from $270,000 to $400,000, an increase of $130,000.
Compensation Committee approved the change on September 24, 2026.
The new salary takes effect September 28, 2026.
Filing dated September 25, 2026, signed by CFO Constantine Petropoulos.
H.B. Fuller appointed R. Jeffrey Bailly, former CEO of UFP Technologies, as a Class I director effective September 23, 2026, and he joins the Audit and Compensation Committees. Director Ruth S. Kimmelshue resigned from the board effective immediately, and the company said her departure was not due to any disagreement. The change adds a director with medical technology and M&A experience, which the company says supports its shift toward higher-growth, higher-margin end markets.
Bailly, age 64, elected as a Class I director on September 23, 2026, with a term expiring at the 2027 annual meeting
Bailly receives a $100,000 annual cash retainer, an initial grant of 1,300 restricted stock units, and an annual deferred phantom stock grant valued at $165,000
Kimmelshue resigned effective immediately; the company said she served on the board for nearly a decade
Adicet Bio reported preliminary Phase 1 data for prula-cel, an investigational cell therapy, in 22 efficacy-evaluable patients with systemic lupus erythematosus, with or without lupus nephritis, using an August 28, 2026 data cut-off. The company plans to start pivotal study start-up activities for lupus nephritis in the fourth quarter of 2026, and the filing says the high DORIS remission rate may support including lupus patients without nephritis. The data are early, from a small group, and the filing contains no revenue or cash figures.
22 efficacy-evaluable patients (16 with lupus nephritis, 6 with extra-renal SLE); follow-up ranged from 6 to 21 months; data cut-off August 28, 2026.
At 12 months, 50% of evaluable lupus nephritis patients achieved a complete renal response and 54% of evaluable patients achieved DORIS remission.
Among 24 safety-evaluable patients, no cytokine release syndrome above Grade 2 was reported; Grade 1 or 2 CRS occurred in 25%; infections occurred in 54%, with Grade 3 or higher in 8.3%.
Pivotal lupus nephritis study start-up activities are planned for Q4 2026; a mid-2027 clinical data update in LN/SLE is anticipated.
4D Molecular Therapeutics said first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema, and reported 2-year data from the SPECTRA trial. The SPECTRA results cover a small group of 9 patients at the Phase 3 dose, and the company describes the 75% treatment burden reduction as a retrospective estimate.
4SIGHT is a global Phase 3 trial with 514 treatment-naive DME patients, comparing 4D-150 against aflibercept 2 mg Q8W.
SPECTRA 2-year safety (N=22): no intraocular inflammation and no ocular serious adverse events reported.
At the Phase 3 dose (n=9), mean BCVA gain was +10.8 letters and mean CST reduction was -176 µm.
Reported supplemental injections were 61% lower than the 13.0 projected with on-label aflibercept; 2 of 9 (22%) patients remained injection-free.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.